Michael R. Feldschuh, Director
Michael Feldschuh earned his bachelors degree in Pre-Med studies at Columbia College, Columbia University in 1991. Prior to joining Daxor’s executive team in December of 2014 he served as a member of the board of directors for one and a half years prior. Michael headed his own hedge fund, Aristarc Capital, from 2009 to 2013 specializing in quantitative strategies. Prior to founding his own fund, Michael was a Managing Director at Morgan Stanley from 2005 to 2009 and also served as a Managing Director and Portfolio Manager at Millennium Partners in New York from 1997-2005. Michael was a proprietary trader for Morgan Stanley & Co. from 1994-1997. Michael began his career at D.E. Shaw & Co. in New York, where he worked with Jeffery Bezos prior to Bezos’s founding of Amazon.
Henry D. Cremisi, MD, FACP
Dr. Cremisi is currently a Medical Director (Renal) at AstraZeneca Pharmaceuticals with over 32 years of experience in medicine. Prior, Dr. Cremisi served as Chairman of Medical Education and a Nephrologist and Hospitalist for Novant Health in Charlotte, North Carolina. He is a Fellow of the American College of Physicians and certified by the American Board of Internal Medicine in both internal medicine and nephrology. Dr. Cremisi has many scientific and professional memberships including the International Society of Nephrology, American Society of Nephrology, Cardiorenal Society of America, Heart Failure Society of America, Society of Hospital Medicine, American College of Physicians, Renal Physicians Association and the American Medical Association. Dr. Cremisi graduated from Tufts University School of Medicine and did his residency at Emory Healthcare in internal medicine.
Jonathan Feldschuh, Chief Scientific Officer
Jonathan Feldschuh has been involved with developing Daxor’s technology for many years. He is a co-inventor on multiple Daxor patents, including the original patent covering the blood volume analyzer (BVA-100). Jonathan studied Physics at Harvard University, receiving an A.B. degree summa cum laude in 1986. Prior to taking on the role of CSO at Daxor, Jonathan worked extensively in technology and quantitative finance. He was the Chief Quantitative Office at Aristarc Capital, overseeing the research, development, and execution of quantitative trading strategies. Prior to Aristarc he worked in quantitative roles at financial firms such as Morgan Stanley, Millennium Partners, and American Express.
Edward S. Feuer, Director
Edward is a CPA and a Managing Partner of Feuer & Orlando LLP. Edward is a member of the AICPA and The New York State Society of Certified Public Accountants where he has served on the State and Local Tax Committee and the Continuity of Practice Committee. Edward graduated from George Washington University and Scarsdale High School. Prior to founding this firm Edward worked at the NYS Department of Taxation and Finance, Westvaco Corp., as well as two metropolitan CPA firms.His areas of specialty are professional service companies, broker dealers, mutual funds, high net worth individuals, wealth management, financial planning, business management and advisory. He reviews all financial statements issued by the firm. Edward is proud of the teamwork of the firm and its focus on the success of their clients. Having more than 35 years of experience, Edward is seen by his clients as their trusted advisor. He is a strong proponent of the importance of client relationships. Loyal and appreciative clients are the hallmark of the firm’s growth.
Joy Goudie, Esq
Joy Goudie is currently a partner at Wissing Miller, LLP, following twelve years as Senior Patent Counsel for Revlon leading cross-functional teams in the US and Spain. In addition, she served as Vice President managing Revlon’s global R&D portfolio and driving new technologies. A published scientist, Ms. Goudie has worked with patents and R&D teams in the development of new antibiotics and small molecules for treatment of solid tumor cancers. Ms. Goudie earned her JD degree from Pace University, has a Masters Degree in Chemistry from Long Island University and graduated from Mercy College with a BS in Medical Technology, Behavioral Science and Health Service Management.
James A. Lombard, Director
James A. Lombard holds an undergraduate degree in Business Administration (BBA) from Iona College and a Master’s Degree (MBA) in Marketing, Banking, and Finance from New York University Graduate School of Business Administration. Mr. Lombard recently retired as Director, Administrative Services Division, City Council of New York and actively participates in civic and community affairs. Prior to joining the City Council, he worked in the field of banking, holding various administrative positions with Citicorp and other major Banking institutions.
Caleb DesRosiers, JD, MPA
Caleb DesRosiers is currently a Senior Principal at Valuate Healthcare Consultancy and serves on the board of the Health Alliance Plan of Michigan and advisory boards of Copilot Provider Support Services, Inc., and TruLite Health. He began his career in state government working on policy to expand healthcare access and prescription drug benefit to seniors and spent five years in the life science industry at Pfizer and Roche supporting brand teams cross-functional payment policy, advocacy, managed care and commercial initiatives. He holds a B.A., Master in Public Administration, and law degrees from Suffolk University.
As the pioneer in blood volume analysis, Daxor provides education and the resources needed to ensure easy onboarding along with continuing support to drive maximum value from your BVA system throughout your facility. With a long-standing commitment to improving care and numerous studies validating our technology, Daxor is completely focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. Our vision is optimal blood volume for all.
Call us at 865-425-0555.
Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions.